Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 11/20 | 0.54 |
| ▸ | CDK2 | P24941 | 11/20 | 0.54 |
| ▸ | GSK3B | P49841 | 8/20 | 0.54 |
| ▸ | VHL | P40337 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21696556 | 1.00 | CCNE1 (0.54) | CCNE1CDK2GSK3BVHLSMN1; SMN2 | |
| SCHEMBL21696706 | 0.95 | CCNE1 (0.54) | CCNE1CDK2GSK3BVHLSMN1; SMN2 | |
| SCHEMBL15112607 | 0.87 | VHL (0.55) | CCNE1CDK2GSK3BVHLKMT2A | |
| SCHEMBL21696674 | 0.85 | VHL (0.50) | CCNE1CDK2GSK3BVHLKMT2A | |
| SCHEMBL15126220 | 0.85 | VHL (0.53) | CCNE1CDK2GSK3BVHLHPGD | |
| SCHEMBL21697138 | 0.84 | CCNE1 (0.47) | CCNE1CDK2GSK3BVHL | |
| SCHEMBL13570435 | 0.84 | VHL (0.52) | CCNE1CDK2GSK3BVHL | |
| SCHEMBL21696738 | 0.84 | VHL (0.52) | CCNE1CDK2GSK3BVHL | |
| SCHEMBL26241389 | 0.82 | VHL (0.53) | CCNE1CDK2GSK3BVHL | |
| SCHEMBL21696618 | 0.82 | VHL (0.53) | CCNE1CDK2GSK3BVHLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-3608317-A1 | COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | Yale University (US) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | CCNE1 1778/4885CDK2 587/4885GSK3B 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.